Research in Werbovetz’s group focuses on the discovery and development of new drug candidates against the protozoan parasitic diseases leishmaniasis, trypanosomiasis and malaria. Their most recent concentrate on visceral leishmaniasis (VL) and human African trypanosomiasis (HAT).
Karl Werbovetz, PhD
Ohio State Global One Health
College of Pharmacy
Medicinal Chemistry and Pharmacognosy
Area of expertise: